NRG Oncology / RTOG 0232 is a
phase III, multi-institutional trial conducted at 68 cancer centers throughout the U.S. and Canada from 2003 to 2012 to assess whether adding EBT to transperineal interstitial permanent brachytherapy conveyed an
additional benefit in progression free survival (PFS), or control
of the cancer growth, at five years following
treatment.